TSE: 3349 - COSMOS Pharmaceutical Corporation

Yield per half year: -47.55%
Sector: Healthcare

Company Analysis COSMOS Pharmaceutical Corporation

Download the report: word Word pdf PDF

1. Summary

Advantages

  • Current debt level 6.27% is below 100% and has decreased over 5 years from 6.86%.
  • The company's current efficiency (ROE=10.57%) is higher than the sector average (ROE=-10.46%)

Disadvantages

  • Price (13755 Β₯) is higher than fair price (3010.96 Β₯)
  • Dividends (1.3%) are below the sector average (2.62%).
  • The stock's return over the last year (-47.03%) is lower than the sector average (-5.32%).

Similar companies

Astellas Pharma Inc.

Takeda Pharmaceutical Company Limited

HOYA Corporation

Daiichi Sankyo Company, Limited

2. Share price and performance

2.1. Share price

2.2. News

No news yet

2.3. Market efficiency

COSMOS Pharmaceutical Corporation Healthcare Index
7 days -2% -0% 1%
90 days -42.9% -0% 7.9%
1 year -47% -5.3% 20.2%

3349 vs Sector: COSMOS Pharmaceutical Corporation has significantly underperformed the "Healthcare" sector by -41.71% over the past year.

3349 vs Market: COSMOS Pharmaceutical Corporation has significantly underperformed the market by -67.21% over the past year.

Stable price: 3349 is not significantly more volatile than the rest of the market on "Tokyo Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.

Long period: 3349 with weekly volatility of -0.9045% over the past year.

3. Summary of the report

3.1. General

P/E: 20.86
P/S: 0.5286

3.2. Revenue

EPS 308.61
ROE 10.57%
ROA 5.13%
ROIC 12.41%
Ebitda margin 5.33%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Above fair price: The current price (13755 Β₯) is higher than the fair price (3010.96 Β₯).

Price is higher than fair: The current price (13755 Β₯) is 78.1% higher than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (20.86) is lower than that of the sector as a whole (111.03).

P/E vs Market: The company's P/E (20.86) is lower than that of the market as a whole (101.86).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (2.2) is lower than that of the sector as a whole (70.29).

P/BV vs Market: The company's P/BV (2.2) is lower than that of the market as a whole (67.75).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (0.5286) is lower than that of the sector as a whole (75.03).

P/S vs Market: The company's P/S indicator (0.5286) is lower than that of the market as a whole (67.66).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (9.56) is lower than that of the sector as a whole (76.71).

EV/Ebitda vs Market: The company's EV/Ebitda (9.56) is lower than that of the market as a whole (113.45).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Rising and has grown by 5.49% over the last 5 years.

Earnings Slowdown: The last year's return (2.76%) is below the 5-year average return (5.49%).

Profitability vs Sector: The return for the last year (2.76%) exceeds the return for the sector (-1.55%).

5.4. ROE

ROE vs Sector: The company's ROE (10.57%) is higher than that of the sector as a whole (-10.46%).

ROE vs Market: The company's ROE (10.57%) is higher than that of the market as a whole (2.63%).

5.5. ROA

ROA vs Sector: The company's ROA (5.13%) is higher than that of the sector as a whole (-10.03%).

ROA vs Market: The company's ROA (5.13%) is higher than that of the market as a whole (3.68%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (12.41%) is higher than that of the sector as a whole (9.09%).

ROIC vs Market: The company's ROIC (12.41%) is higher than that of the market as a whole (8.77%).

6. Finance

6.1. Assets and debt

Debt level: (6.27%) is quite low in relation to assets.

Debt reduction: over 5 years, the debt has decreased from 6.86% to 6.27%.

Excess of debt: The debt is not covered by net income, percentage 122.26%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 1.3% is below the average for the sector '2.62%.

7.2. Stability and increase in payments

Dividend stability: The company's dividend yield 1.3% has been steadily paid over the past 7 years, DSI=0.86.

Weak dividend growth: The company's dividend yield 1.3% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (19.05%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

No insider transactions have been recorded yet

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum COSMOS Pharmaceutical Corporation

9.3. Comments